PREVIEW

New Analysis Suggests Long-Term Effectiveness for Wegovy Users. NBC reports that patients taking Novo Nordisk's obesity treatment maintain an average of 10% weight loss over four years. The news potentially boosts the drugmaker's push for Wegovy to be covered by insurers and governments. The company submitted long-term findings at the European Congress on Obesity in Venice, Italy. "This is the longest study we’ve conducted so far of semaglutide for weight loss." "We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug." Martin Holst Lange, Novo’s head of development, via NBC. According to another analysis published by the drugmaker, approximately 17% of trial participants stopped using the treatment due to side effects like nausea. The costly treatment ranges from $200 to nearly $2,000 per month in the ten countries where the drug is available. NBC reports that Novo Nordisk was the first drugmaker to market GLP-1 agonists, originally developed as a diabetes treatment, to address record high obesity rates. Rival Eli Lilly launched its drug Zepbound in the United States in December of 2023. Neither drugmaker has managed to produce enough of the treatment to meet surging demand. THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT